• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IgD 型骨髓瘤:基于日本患者分析的临床特征及新分期系统

IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.

作者信息

Shimamoto Y

机构信息

Department of Internal Medicine, Saga Medical School, Japan.

出版信息

Cancer Detect Prev. 1995;19(5):426-35.

PMID:7585729
Abstract

The aim of this review was to compare the clinical characteristics and prognostic factors of Japanese and Western IgD myeloma patients, and also to introduce our new staging system, based on the analysis of Japanese patients. We reviewed 165 Japanese with IgD myeloma reported since the first Japanese case report in 1967 and compared these patients with Western IgD myeloma patients reported in the literature. Parameters evaluated were recorded at diagnosis. The staging systems of Durie and Salmon and the British Medical Research Council (BMRC) were also applied to our series. Survival curves were calculated according to the method of Kaplan & Meier and generalized Wilcoxon test and log-rank test were used to assess differences in survival. Multivariate analysis was performed by the Cox proportional hazard model. We were able to confirm the similarity of clinical features in Japanese patients and those reported in Western countries. We did, however, find small differences in the incidence of lymphadenopathy, thrombocytopenia, and high serum levels of creatinine, and in the 5-year survival rates. Assessment of prognostic factors influencing survival was compared in Japanese and Western patients. A multiple regression model in our series showed that light chain subtype and leukocyte count had a strong predictive relationship for duration of survival. A new risk grouping using these two major factors was introduced since neither the common staging system of Durie & Salmon nor those of the BMRC predicted survival in these patients; to date, there are still no reports from Western countries in this regard.

摘要

本综述的目的是比较日本和西方IgD骨髓瘤患者的临床特征和预后因素,并在对日本患者进行分析的基础上介绍我们新的分期系统。我们回顾了自1967年日本首例病例报告以来报道的165例日本IgD骨髓瘤患者,并将这些患者与文献中报道的西方IgD骨髓瘤患者进行了比较。评估的参数在诊断时记录。Durie和Salmon分期系统以及英国医学研究委员会(BMRC)分期系统也应用于我们的病例系列。根据Kaplan & Meier方法计算生存曲线,并使用广义Wilcoxon检验和对数秩检验评估生存差异。通过Cox比例风险模型进行多变量分析。我们能够证实日本患者与西方国家报道的患者临床特征相似。然而,我们确实发现淋巴结病、血小板减少症和血清肌酐水平升高的发生率以及5年生存率存在微小差异。对影响日本和西方患者生存的预后因素进行了比较评估。我们病例系列中的多元回归模型显示,轻链亚型和白细胞计数与生存持续时间有很强的预测关系。由于Durie & Salmon的常用分期系统和BMRC的分期系统均无法预测这些患者的生存情况,因此引入了一种使用这两个主要因素的新风险分组方法;迄今为止,西方国家在这方面尚无相关报道。

相似文献

1
IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.IgD 型骨髓瘤:基于日本患者分析的临床特征及新分期系统
Cancer Detect Prev. 1995;19(5):426-35.
2
Prognostic factors and staging systems of multiple myeloma:多发性骨髓瘤的预后因素及分期系统:
Chin Med J (Engl). 2007 Oct 5;120(19):1655-8.
3
International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.国际预后指数(IPI)——与270例接受传统化疗的患者群体中五种多发性骨髓瘤分期系统的关键比较。
Neoplasma. 2006;53(4):277-84.
4
[Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].多发性骨髓瘤临床分期系统的预后分析与评估——附206例报告
Ai Zheng. 2006 Apr;25(4):461-4.
5
International staging system for multiple myeloma.多发性骨髓瘤国际分期系统
J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4.
6
[Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].[新国际分期系统在多发性骨髓瘤中的预后价值。与杜里-萨尔蒙分期系统的比较]
Rev Med Chil. 2008 Jan;136(1):7-12. Epub 2008 Apr 30.
7
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.利用游离β2微球蛋白的HLA I类重链血清水平以及IgM或血小板计数对活动性疾病的多发性骨髓瘤患者进行分期。
Blood Cells Mol Dis. 2009 Jan-Feb;42(1):71-6. doi: 10.1016/j.bcmd.2008.09.003. Epub 2008 Nov 7.
8
Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?磁共振成像作为杜里和萨尔蒙临床分期系统的补充?
Cancer. 2002 Sep 15;95(6):1334-45. doi: 10.1002/cncr.10818.
9
[Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Ann Ital Med Int. 1990 Jul-Sep;5(3 Pt 1):195-204.
10
DNA-image cytometry and clinical staging systems in multiple myeloma.多发性骨髓瘤中的DNA图像细胞计量术与临床分期系统
Anticancer Res. 1994 Sep-Oct;14(5B):2183-8.

引用本文的文献

1
A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.环状 RNA 结合蛋白 HNRNPU 编码的一种新型蛋白通过调控骨髓微环境和可变剪接促进多发性骨髓瘤进展。
J Exp Clin Cancer Res. 2022 Mar 8;41(1):85. doi: 10.1186/s13046-022-02276-7.
2
Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma.使用流式细胞术检测细胞内 IgD 可能是诊断 IgD 多发性骨髓瘤的一种新颖且补充的方法。
BMC Cancer. 2018 Jun 11;18(1):650. doi: 10.1186/s12885-018-4562-8.